Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model

Tullia C. Bruno, Cristin Rothwell, Joseph F. Grosso, Derese Getnet, Hung Rong Yen, Nicholas M. Durham, George Netto, Andrew Mark Pardoll, Charles G. Drake

Research output: Contribution to journalArticle

Abstract

Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-Î production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. Results: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. Conclusions: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.

Original languageEnglish (US)
Pages (from-to)514-522
Number of pages9
JournalProstate
Volume72
Issue number5
DOIs
StatePublished - Apr 2012

Fingerprint

Prostatic Neoplasms
T-Lymphocytes
Prostate
Neoplasms
Phenotype
Antigens
Tumor Burden
Transgenic Mice
Flow Cytometry
Maintenance
Population

Keywords

  • anergy
  • Clone 4
  • hemagglutinin
  • tolerance
  • TRAMP

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Bruno, T. C., Rothwell, C., Grosso, J. F., Getnet, D., Yen, H. R., Durham, N. M., ... Drake, C. G. (2012). Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate, 72(5), 514-522. https://doi.org/10.1002/pros.21453

Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. / Bruno, Tullia C.; Rothwell, Cristin; Grosso, Joseph F.; Getnet, Derese; Yen, Hung Rong; Durham, Nicholas M.; Netto, George; Pardoll, Andrew Mark; Drake, Charles G.

In: Prostate, Vol. 72, No. 5, 04.2012, p. 514-522.

Research output: Contribution to journalArticle

Bruno, TC, Rothwell, C, Grosso, JF, Getnet, D, Yen, HR, Durham, NM, Netto, G, Pardoll, AM & Drake, CG 2012, 'Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model', Prostate, vol. 72, no. 5, pp. 514-522. https://doi.org/10.1002/pros.21453
Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM et al. Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate. 2012 Apr;72(5):514-522. https://doi.org/10.1002/pros.21453
Bruno, Tullia C. ; Rothwell, Cristin ; Grosso, Joseph F. ; Getnet, Derese ; Yen, Hung Rong ; Durham, Nicholas M. ; Netto, George ; Pardoll, Andrew Mark ; Drake, Charles G. / Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. In: Prostate. 2012 ; Vol. 72, No. 5. pp. 514-522.
@article{2bd188a044ac486f949c93a6697b231c,
title = "Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model",
abstract = "Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-{\^I} production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. Results: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. Conclusions: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.",
keywords = "anergy, Clone 4, hemagglutinin, tolerance, TRAMP",
author = "Bruno, {Tullia C.} and Cristin Rothwell and Grosso, {Joseph F.} and Derese Getnet and Yen, {Hung Rong} and Durham, {Nicholas M.} and George Netto and Pardoll, {Andrew Mark} and Drake, {Charles G.}",
year = "2012",
month = "4",
doi = "10.1002/pros.21453",
language = "English (US)",
volume = "72",
pages = "514--522",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model

AU - Bruno, Tullia C.

AU - Rothwell, Cristin

AU - Grosso, Joseph F.

AU - Getnet, Derese

AU - Yen, Hung Rong

AU - Durham, Nicholas M.

AU - Netto, George

AU - Pardoll, Andrew Mark

AU - Drake, Charles G.

PY - 2012/4

Y1 - 2012/4

N2 - Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-Î production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. Results: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. Conclusions: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.

AB - Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-Î production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. Results: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. Conclusions: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.

KW - anergy

KW - Clone 4

KW - hemagglutinin

KW - tolerance

KW - TRAMP

UR - http://www.scopus.com/inward/record.url?scp=84857505184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857505184&partnerID=8YFLogxK

U2 - 10.1002/pros.21453

DO - 10.1002/pros.21453

M3 - Article

VL - 72

SP - 514

EP - 522

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 5

ER -